Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.3            MARKET SCOPE
1.3.1             MARKETS COVERED.. 19
1.3.2             YEARS CONSIDERED FOR THE STUDY
1.4            CURRENCY
1.5            STAKEHOLDERS
1.6            LIMITATIONS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH APPROACH
2.1.1             SECONDARY RESEARCH
2.1.1.1           KEY DATA FROM SECONDARY SOURCES
2.1.2             PRIMARY RESEARCH. 24
2.1.2.1           KEY DATA FROM PRIMARY SOURCES
2.1.2.2           BREAK DOWN OF PRIMARIES
2.1.2.3           KEY INDUSTRY INSIGHTS
2.2            MARKET SIZE ESTIMATION
2.3            DATA TRIANGULATION APPROACH
2.4            MARKET SHARE ESTIMATION
2.5            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            CUSTOM ANTIBODIES: MARKET OVERVIEW
4.2            CUSTOM ANTIBODIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.3            REGIONAL MIX: CUSTOM ANTIBODIES MARKET (2018–2023)
4.4            CUSTOM ANTIBODIES MARKET: DEVELOPED VS. DEVELOPING MARKETS,
2018 VS. 2023

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1             MARKET DRIVERS
5.2.1.1           INCREASING RESEARCH ACTIVITY AND FUNDING
5.2.1.2           QUALITY CONCERNS OVER CATALOG ANTIBODIES
5.2.1.3           INCREASING ANTIBODY THERAPEUTICS AND EXPANDING DRUG PIPELINE
5.2.1.4           GROWING INDUSTRY-ACADEMIA COLLABORATIONS
5.2.2             MARKET OPPORTUNITIES
5.2.2.1           HIGH GROWTH OPPORTUNITIES IN EMERGING COUNTRIES
5.2.2.2           INCREASING DEMAND FOR PERSONALIZED MEDICINE AND PROTEIN THERAPEUTICS
5.2.2.3           GROWTH IN STEM CELL AND CVD RESEARCH
5.2.2.4           INCREASING FOCUS ON BIOMARKER DISCOVERY
5.2.3             MARKET CHALLENGES. 47
5.2.3.1           COST- AND TIME-INTENSIVE ANTIBODY DEVELOPMENT PROCESSES
5.2.3.2           PRESENCE OF ANTIBODY ALTERNATIVES
5.2.4             INDUSTRY TRENDS. 49
5.2.4.1           INCREASING FOCUS ON ANTIBODY-DRUG CONJUGATES (ADCS)
5.2.4.2           DEVELOPMENT OF BISPECIFIC ANTIBODIES

6.... CUSTOM ANTIBODY MARKET, BY SERVICE

6.1            INTRODUCTION
6.2            ANTIBODY DEVELOPMENT
6.2.1             ANTIBODY CHARACTERIZATION
6.2.1.1           CHARACTERIZATION ELIMINATES ANTIBODIES WITH HETEROGENEITIES THAT MAY HAMPER RESEARCH STUDIES; THIS IS DRIVING MARKET GROWTH
6.2.2             ANTIGEN PREPARATION
6.2.2.1           ANTIGEN PREPARATION FORMS ONE OF THE MOST IMPORTANT STEPS IN THE ANTIBODY PRODUCTION PROCESS
6.2.3             IMMUNIZATION & HYBRIDOMA PRODUCTION
6.2.3.1           SPECIFIC IMMUNIZATION PROTOCOLS ARE FOLLOWED DEPENDING ON THE ANTIBODY REQUIRED AND ANIMAL USED TO GENERATE THEM
6.3            ANTIBODY PRODUCTION & PURIFICATION
6.4            ANTIBODY FRAGMENTATION & LABELING

7.... CUSTOM ANTIBODY MARKET, BY TYPE

7.1            INTRODUCTION
7.2            MONOCLONAL ANTIBODIES
7.2.1             MONOCLONAL ANTIBODIES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
7.3            POLYCLONAL ANTIBODIES
7.3.1             POLYCLONAL ABS ARE PREFERRED IN PROTEOMIC RESEARCH FOR DETECTION OF DENATURED PROTEINS. 64
7.4            RECOMBINANT ANTIBODIES
7.4.1             RESEARCH REPRODUCIBILITY OFFERED BY THESE ANTIBODIES IS DRIVING THE GROWTH OF THE RECOMBINANT ANTIBODIES SEGMENT
7.5            OTHER CUSTOM ANTIBODIES

8.... CUSTOM ANTIBODY MARKET, BY SOURCE

8.1            INTRODUCTION
8.2            MICE
8.2.1             MICE ARE THE MOST PREFERRED HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION
8.3            RABBITS
8.3.1             ANTIBODIES DEVELOPED IN RABBITS ELIMINATE THE LIMITATION OF SELF-ANTIGEN RECOGNITION IN HUMANS
8.4            OTHER SOURCES

9.... CUSTOM ANTIBODY MARKET, BY RESEARCH AREA

9.1            INTRODUCTION
9.2            ONCOLOGY
9.2.1             USE OF ANTIBODIES HAS GROWN CONSIDERABLY IN CANCER RESEARCH
9.3            INFECTIOUS DISEASES
9.3.1             ANTIBODIES ARE WIDELY USED IN R&D FOR THE DEVELOPMENT OF VACCINES & THERAPEUTICS AGAINST VARIOUS INFECTIOUS DISEASES
9.4            IMMUNOLOGY
9.4.1             ASSESSMENT OF CELL SURFACE ANTIGENS USING ANTIBODIES FORMS AN IMPORTANT FIELD OF RESEARCH IN IMMUNOLOGY
9.5            NEUROBIOLOGY
9.5.1             NEUROBIOLOGY FORMS ONE OF THE FASTEST-GROWING SEGMENTS IN TERMS OF RESEARCH BEING UNDERTAKEN UTILIZING ANTIBODIES
9.6            STEM CELLS
9.6.1             AVAILABILITY OF HIGH-QUALITY ANTIBODIES HAS BOOSTED STEM CELL RESEARCH
9.7            CARDIOVASCULAR DISEASES
9.7.1             IDENTIFICATION & CHARACTERIZATION OF CVD BIOMARKERS IS AN IMPORTANT RESEARCH AREA UTILIZING ANTIBODIES
9.8            OTHER RESEARCH AREAS

10.. CUSTOM ANTIBODY MARKET, BY END USER

10.1          INTRODUCTION
10.2          PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF CUSTOM ANTIBODIES
10.3          ACADEMIC & RESEARCH INSTITUTES
10.3.1           INCREASE IN DNA SEQUENCING STUDIES AND PROTEOMIC RESEARCH TO DRIVE MARKET GROWTH
10.4          CONTRACT RESEARCH ORGANIZATIONS
10.4.1           CROS PROVIDE AFFORDABLE OUTLETS FOR COMPANIES AND ACADEMIA TO PURSUE NEW MEDICINES AND OFFER A COST-EFFECTIVE SOLUTION TO DEVELOP DRUGS

11.. CUSTOM ANTIBODY MARKET, BY REGION

11.1          INTRODUCTION
11.2          NORTH AMERICA
11.2.1           US
11.2.1.1         GROWING RESEARCH IN THE FIELD OF STRUCTURE-BASED DRUG DESIGN AND THERAPEUTIC MABS TO DRIVE MARKET GROWTH
11.2.2           CANADA
11.2.2.1         INCREASING GENOMIC RESEARCH TO DRIVE THE ADOPTION OF CUSTOM ANTIBODIES IN THE COMING YEARS
11.3          EUROPE
11.3.1           GERMANY
11.3.1.1         HIGH INVESTMENTS FOR THE DEVELOPMENT OF ADCS SUPPORT THE GROWTH OF THE CUSTOM ANTIBODIES MARKET IN GERMANY
11.3.2           UK
11.3.2.1         GROWING RESEARCH INVESTMENTS TO DRIVE GROWTH IN THE LIFE SCIENCE RESEARCH MARKET, RESULTING IN THE GROWING USE OF ANTIBODIES
11.3.3           FRANCE
11.3.3.1         EXPANDING PIPELINE OF THERAPEUTIC MABS ALONG WITH INCREASING INVESTMENTS IN RESEARCH ARE SUPPORTING MARKET GROWTH
11.3.4           ITALY
11.3.4.1         GROWING PROTEOMICS AND GENOMICS RESEARCH AT THE ACADEMIC LEVEL TO PLAY A KEY ROLE IN MARKET GROWTH IN ITALY
11.3.5           SPAIN
11.3.5.1         INCREASING FOCUS ON THE ADVANCEMENT OF TRANSLATIONAL PERSONALIZED MEDICINE IS EXPECTED TO DRIVE MARKET GROWTH
11.3.6           REST OF EUROPE
11.4          ASIA PACIFIC
11.4.1           JAPAN
11.4.1.1         LARGE NUMBER OF RESEARCH INITIATIVES TOWARDS THE DEVELOPMENT OF VARIOUS ADCS SUPPORT MARKET GROWTH IN JAPAN
11.4.2           CHINA
11.4.2.1         CHINA IS ONE OF THE FASTEST-GROWING MARKETS IN THE RESEARCH SECTOR AND IS EXPECTED TO DOMINATE THE MARKET IN THE COMING YEARS
11.4.3           INDIA
11.4.3.1         RESEARCH FOR GENERIC MABS AND FUSION MABS AS THERAPEUTICS IS EXPECTED TO PROPEL THE CUSTOM ANTIBODIES MARKET IN THE COUNTRY
11.4.4           REST OF ASIA PACIFIC
11.5          LATIN AMERICA
11.5.1           INCREASING APPLICATIONS OF RESEARCH-SPECIFIC CUSTOM ANTIBODIES TO DRIVE THE GROWTH OF THE MARKET IN THE REGION
11.6          MIDDLE EAST & AFRICA
11.6.1           GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON THE AFRICAN MARKET IS DRIVING THE MARKET FOR CUSTOM ANTIBODIES IN THE REGION

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          MARKET SHARE ANALYSIS
12.3          COMPETITIVE SITUATION AND TRENDS
12.3.1           PRODUCT & SERVICES LAUNCHES
12.3.2           EXPANSIONS
12.3.3           ACQUISITIONS
12.3.4           OTHER STRATEGIES

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, SERVICES OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW)*
13.1          THERMO FISHER SCIENTIFIC INC.
13.2          GENSCRIPT
13.3          ABCAM PLC
13.4          MERCK GROUP
13.5          BIO-RAD LABORATORIES, INC.
13.6          CELL SIGNALING TECHNOLOGY, INC.
13.7          AGILENT TECHNOLOGIES, INC.
13.8          BIOLEGEND, INC.
13.9          ROCKLAND IMMUNOCHEMICALS INC.
13.10        PROMAB BIOTECHNOLOGIES, INC.
13.11        PROTEOGENIX
13.12        INNOVAGEN AB
*BUSINESS OVERVIEW, SERVICES OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
14            APPENDIX

LIST OF TABLES

TABLE 1              MARKET DRIVERS: IMPACT ANALYSIS
TABLE 2              MARKET OPPORTUNITIES: IMPACT ANALYSIS
TABLE 3              MARKET CHALLENGES: IMPACT ANALYSIS
TABLE 4              CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION)
TABLE 5              ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 6              ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
TABLE 7              ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 8              ANTIGEN PREPARATION MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
TABLE 9              IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 10            ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 11            ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 12            CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 13            CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 14            CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 15            CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 16            OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
TABLE 17            CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 18            CUSTOM ANTIBODIES MARKET FOR MICE, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 19            CUSTOM ANTIBODIES MARKET FOR RABBITS, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 20            CUSTOM ANTIBODIES MARKET FOR OTHER SOURCES, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 21            CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016–2023 (USD MILLION)
TABLE 22            CUSTOM ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 23            CUSTOM ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 24            CUSTOM ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 25            CUSTOM ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 26            CUSTOM ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 27            CUSTOM ANTIBODIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,  2016–2023 (USD MILLION)
TABLE 28            CUSTOM ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY,  2016–2023 (USD MILLION)
TABLE 29            CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION)
TABLE 30            CUSTOM ANTIBODIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2023 (USD MILLION)
TABLE 31            CUSTOM ANTIBODIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION)
TABLE 32            CUSTOM ANTIBODIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, 
BY COUNTRY, 2016–2023 (USD MILLION)
TABLE 33            CUSTOM ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
TABLE 34            NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY COUNTRY, 
2016–2023 (USD MILLION)
TABLE 35            NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 
2016–2023 (USD MILLION)
TABLE 36            NORTH AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 
2016–2023 (USD MILLION)
TABLE 37            NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 38            NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 
2016–2023 (USD MILLION)
TABLE 39            NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 40            NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY END USER, 
2016–2023 (USD MILLION)
TABLE 41            US: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION)
TABLE 42            US: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 43            US: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 44            US: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 45            US: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 46            US: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION)
TABLE 47            CANADA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 103
TABLE 48            CANADA: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 49            CANADA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 50            CANADA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 51            CANADA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 52            CANADA: CUSTOM ANTIBODIES MARKET, BY END USER,
2016–2023 (USD MILLION)
TABLE 53            EUROPE: CUSTOM ANTIBODIES MARKET, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 54            EUROPE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 107
TABLE 55            EUROPE: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 56            EUROPE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 57            EUROPE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 58            EUROPE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 59            EUROPE: CUSTOM ANTIBODIES MARKET, BY END USER,
2016–2023 (USD MILLION)
TABLE 60            GERMANY: CUSTOM ANTIBODIES MARKET, BY SERVICE,
2016–2023 (USD MILLION)
TABLE 61            GERMANY: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 62            GERMANY: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 63            GERMANY: CUSTOM ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION)
TABLE 64            GERMANY: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 65            GERMANY: CUSTOM ANTIBODIES MARKET, BY END USER,
2016–2023 (USD MILLION)
TABLE 66            UK: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION)
TABLE 67            UK: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 68            UK: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 69            UK: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 70            UK: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 71            UK: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION)
TABLE 72            FRANCE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 117
TABLE 73            FRANCE: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 74            FRANCE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 75            FRANCE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 76            FRANCE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 77            FRANCE: CUSTOM ANTIBODIES MARKET, BY END USER,
2016–2023 (USD MILLION)
TABLE 78            ITALY: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 120
TABLE 79            ITALY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 80            ITALY: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 81            ITALY: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 82            ITALY: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 83            ITALY: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION) 122
TABLE 84            SPAIN: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 123
TABLE 85            SPAIN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 86            SPAIN: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 87            SPAIN: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 88            SPAIN: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 89            SPAIN: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION) 125
TABLE 90            ROE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION)
TABLE 91            ROE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 92            ROE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 93            ROE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 94            ROE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 95            ROE: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION)
TABLE 96            ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY COUNTRY,
2016–2023 (USD MILLION)
TABLE 97            ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY SERVICE,
2016–2023 (USD MILLION)
TABLE 98            ASIA PACIFIC: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 99            ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 100          ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION)
TABLE 101          ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 102          ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY END USER,
2016–2023 (USD MILLION)
TABLE 103          JAPAN: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 134
TABLE 104          JAPAN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 105          JAPAN: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 106          JAPAN: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 107          JAPAN: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 108          JAPAN: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION) 136
TABLE 109          CHINA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 137
TABLE 110          CHINA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 111          CHINA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 112          CHINA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 113          CHINA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 114          CHINA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION) 139
TABLE 115          INDIA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 140
TABLE 116          INDIA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 117          INDIA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 118          INDIA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 119          INDIA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,
2016–2023 (USD MILLION)
TABLE 120          INDIA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016–2023 (USD MILLION) 142
TABLE 121          ROAPAC: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016–2023 (USD MILLION) 143
TABLE 122          ROAPAC: ANTIBODY DEVELOPMENT MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 123          ROAPAC: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
TABLE 124          ROAPAC: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016–2023 (USD MILLION)
TABLE 125          ROAPAC: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 126          ROAPAC: CUSTOM ANTIBODIES MARKET, BY END USER,
2016–2023 (USD MILLION)
TABLE 127          LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY SERVICE,
2016–2023 (USD MILLION)
TABLE 128          LATIN AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 
2016–2023 (USD MILLION)
TABLE 129          LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY TYPE,
2016–2023 (USD MILLION)
TABLE 130          LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY SOURCE,
2016–2023 (USD MILLION)
TABLE 131          LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2016–2023 (USD MILLION)
TABLE 132          LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY END USER, 
2016–2023 (USD MILLION)
TABLE 133          MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 
2016–2023 (USD MILLION)
TABLE 134          MIDDLE EAST & AFRICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 
2016–2023 (USD MILLION)
TABLE 135          MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY TYPE, 
2016–2023 (USD MILLION)
TABLE 136          MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 
2016–2023 (USD MILLION)
TABLE 137          MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA,  2016–2023 (USD MILLION)
TABLE 138          MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY END USER, 
2016–2023 (USD MILLION)
TABLE 139          CUSTOM ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2017
TABLE 140          PRODUCT AND SERVICE LAUNCHES, 2015–2018
TABLE 141          EXPANSIONS, 2015–2018
TABLE 142          ACQUISITIONS, 2015–2018
TABLE 143          OTHER STRATEGIES, 2015–2018

LIST OF FIGURES

FIGURE 1            CUSTOM ANTIBODY MARKET
FIGURE 2            RESEARCH DESIGN
FIGURE 3            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION
FIGURE 4            BOTTOM-UP APPROACH
FIGURE 5            TOP-DOWN APPROACH
FIGURE 6            DATA TRIANGULATION METHODOLOGY
FIGURE 7            CUSTOM ANTIBODIES MARKET, BY SERVICE, 2018 VS. 2023 (USD MILLION)
FIGURE 8            CUSTOM ANTIBODIES MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
FIGURE 9            CUSTOM ANTIBODIES MARKET, BY SOURCE, 2018 VS. 2023 (USD MILLION)
FIGURE 10          CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 
2018 VS. 2023 (USD MILLION)
FIGURE 11          CUSTOM ANTIBODIES MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
FIGURE 12          GEOGRAPHICAL SNAPSHOT OF THE CUSTOM ANTIBODIES MARKET
FIGURE 13          QUALITY CONCERNS OVER CATALOG ANTIBODIES & THE EXPANDING AB THERAPEUTICS PIPELINE TO DRIVE MARKET GROWTH
FIGURE 14          US DOMINATED THE CUSTOM ANTIBODIES MARKET IN 2017
FIGURE 15          APAC TO REGISTER THE HIGHEST GROWTH RATE DURING
THE FORECAST PERIOD (2018–2023)
FIGURE 16          DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN
2018 & 2023
FIGURE 17          CUSTOM ANTIBODIES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18          R&D INVESTMENTS, BY COUNTRY (USD BILLION)
FIGURE 19          NUMBER OF THERAPEUTIC ANTIBODIES APPROVED FOR MARKET RELEASE (2011–2017)
FIGURE 20          PERSONALIZED MEDICINE PRODUCTS, 2008–2016
FIGURE 21          INCREASING FOCUS ON ADCS & THE DEVELOPMENT OF BISPECIFIC ANTIBODIES ARE THE KEY MARKET TRENDS
FIGURE 22          ANTIBODY DEVELOPMENT SERVICES TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD
FIGURE 23          RECOMBINANT ANTIBODIES SEGMENT IS EXPECTED TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
FIGURE 24          ONCOLOGY TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD   75
FIGURE 25          PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD
FIGURE 26          CUSTOM ANTIBODIES MARKET: GEOGRAPHIC SNAPSHOT (2017)
FIGURE 27          NORTH AMERICA: CUSTOM ANTIBODIES MARKET SNAPSHOT
FIGURE 28          EUROPE: CUSTOM ANTIBODIES MARKET SNAPSHOT
FIGURE 29          ASIA PACIFIC: CUSTOM ANTIBODIES MARKET SNAPSHOT
FIGURE 30          EXPANSIONS—KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO OCTOBER 2018
FIGURE 31          THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 32          GENSCRIPT: COMPANY SNAPSHOT
FIGURE 33          ABCAM PLC: COMPANY SNAPSHOT
FIGURE 34          MERCK GROUP: COMPANY SNAPSHOT
FIGURE 35          BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 36          AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT

当レポートのプレスリリースは発行されておりません。